BHV-4157 Clinical Study

A randomized, double-blind, placebo-controlled trial of adjunctive BHV-4157 in OCD

Contact us at ocdresearch@stanford.edu or 650-723-4095

About the BHV-4157 Study

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This multi-site study of a novel investigational drug for OCD is being conducted at Stanford.

Purpose: To understand whether a new drug, when used as adjunctive therapy, can bring about reduction in OCD symptoms.

This clinical study is listed in clinicaltrials.gov.

PARTICIPATE IN BHV-4157 STUDY

The Stanford Translational OCD Research Program is looking for adults 18-65 years old with OCD to take part in a study providing these possible benefits:

  • Free diagnostic evaluation
  • Receive once a day dosing of the study drug or a matching placebo for 3 months (randomization phase)
  • Receive once a day dosing of the study drug, after completing randomization phase, for 12 months (extension phase)
  • Compensation (randomization phase: up to $450, extension phase: up to $525)
  •  

You can participate if:

  •  You are 18-65 years old
  • You have a primary diagnosis of OCD
  • You have the capacity to provide informed consent
  • You currently experiencing non-response or inadequate response to their current Standard of Care (SOC) medication
  • You are currently on selective serotonin reuptake inhibitor (SSRI) or clomipramine treatment for an adequate duration and at an adequate dose
  • You are able to understand and agree to comply with the prescribed dosage regimens and procedures
  •  

 

You cannot participate if:

  • You have history of psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT)
  • You have a psychiatric or medical conditions that makes participation unsafe
  • You are pregnant or nursing female
  •  
  •  

Duration of Study Involvement

  • Each individual will participate in a free diagnostic evaluation by experienced OCD clinicians
  • If eligible, the study will involve:
  •     Randomization phase:  up to 6 in-person visits and 2 visits via phone occuring over a span of 3 months
  •     Extension phase:             up to 7 in-person visits and 2 visits via phone occuring over a span of 12 months
  •  

Contact US

Address

401 Quarry Rd

Stanford, CA 94305-5715

Email

ocdresearch@stanford.edu 

Phone Number

650-723-4095